Literature DB >> 17996508

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.

Alawi A Alsheikh-Ali1, Jen-Liang Lin, Paul Abourjaily, Dineli Ahearn, Jeffrey T Kuvin, Richard H Karas.   

Abstract

Current guidelines identify low-density lipoprotein (LDL) cholesterol as the primary target for cardiovascular prevention but also recognize low high-density lipoprotein (HDL) cholesterol as an important secondary target. This study was conducted to determine the prevalence of low HDL cholesterol in a contemporary ambulatory high-risk population across various LDL cholesterol levels, including patients taking statins. Screening of 44,052 electronic medical records from a primary care practice identified 1,512 high-risk patients with documented coronary heart disease (CHD) or CHD risk equivalents. Low HDL cholesterol (< or =40 mg/dl in men, < or =50 mg/dl in women) was present in 66% of the 1,512 patients. Low HDL cholesterol was prevalent across all LDL cholesterol levels but most prevalent in patients with LDL cholesterol < or =70 mg/dl (79% vs 66% in those with LDL cholesterol 71 to 100 mg/dl and 64% in patients with LDL cholesterol >100 mg/dl, p <0.01). Low HDL cholesterol was equally and highly prevalent in patients taking statins (67%) and those not taking statins (64%) (p = NS). HDL cholesterol and LDL cholesterol levels correlated poorly (R(2) = 0.01), and this was unaffected by gender or statin treatment. In conclusion, in high-risk patients with CHD or CHD risk equivalents, low HDL cholesterol levels remain prevalent despite statin treatment and the achievement of aggressive LDL cholesterol goals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996508     DOI: 10.1016/j.amjcard.2007.06.058

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  No accord for the ACCORD-Lipid trial results.

Authors:  Glenn Matfin; Matthew Thorne
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

Review 3.  Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.

Authors:  Russell M Medford; T Forcht Dagi; Robert S Rosenson; Margaret K Offermann
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

Review 4.  HDL cholesterol and cardiovascular outcomes: what is the evidence?

Authors:  Melvyn Rubenfire; Robert D Brook
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

5.  Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients.

Authors:  Yu-Hung Chang; Kun-Cheng Lin; Dao-Ming Chang; Chang-Hsun Hsieh; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 6.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

7.  Carotid artery stiffness, high-density lipoprotein cholesterol and inflammation in men with pre-hypertension.

Authors:  K S Heffernan; R H Karas; J T Kuvin; S Y Jae; V J Vieira; B Fernhall
Journal:  J Hum Hypertens       Date:  2009-02-19       Impact factor: 3.012

8.  Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.

Authors:  Anselm K Gitt; Claus Jünger; Wenefrieda Smolka; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-06-03       Impact factor: 5.460

Review 9.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Authors:  Elisavet Moutzouri; Anastazia Kei; Moses S Elisaf; Haralampos J Milionis
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

10.  Prevalence, Characteristics, and In-Hospital Outcomes of Metabolic Syndrome among Patients with Acute Coronary Syndrome in the United Arab Emirates.

Authors:  Abdulla Shehab; Bayan Al-Dabbagh; Wael Almahmeed; Nazar Bustani; Nicolaas Nagelkerke; Abdulla Alnaeemi; Alawi A Alsheikh-Ali
Journal:  Open Cardiovasc Med J       Date:  2012-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.